[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse NFATC4

Summary
SymbolNFATC4
Namenuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4
Aliases NFAT3; NF-AT3; NF-ATC4; T-cell transcription factor NFAT3; Nuclear factor of activated T-cells, cytoplasmic ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Note=Cytoplasmic for the phosphorylated form and nuclear after activation that is controlled by calcineurin-mediated dephosphorylation. Rapid nuclear exit of NFATC is thought to be one mechanism by which cells distinguish between sustained and transient calcium signals. The subcellular localization of NFATC plays a key role in the regulation of gene transcription.
Domain PF16179 Rel homology dimerisation domain
PF00554 Rel homology DNA-binding domain
Function

Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2 and IL-4. Transcriptionally repressed by estrogen receptors; this inhibition is further enhanced by estrogen. Increases the transcriptional activity of PPARG and has a direct role in adipocyte differentiation. May play an important role in myotube differentiation. May play a critical role in cardiac development and hypertrophy. May play a role in deafferentation-induced apoptosis of sensory neurons.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001569 patterning of blood vessels
GO:0001763 morphogenesis of a branching structure
GO:0001819 positive regulation of cytokine production
GO:0006091 generation of precursor metabolites and energy
GO:0007389 pattern specification process
GO:0007507 heart development
GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage
GO:0009314 response to radiation
GO:0009411 response to UV
GO:0009416 response to light stimulus
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010226 response to lithium ion
GO:0010721 negative regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010771 negative regulation of cell morphogenesis involved in differentiation
GO:0010975 regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0015980 energy derivation by oxidation of organic compounds
GO:0016055 Wnt signaling pathway
GO:0016358 dendrite development
GO:0019722 calcium-mediated signaling
GO:0019932 second-messenger-mediated signaling
GO:0021700 developmental maturation
GO:0022604 regulation of cell morphogenesis
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0031345 negative regulation of cell projection organization
GO:0032091 negative regulation of protein binding
GO:0032640 tumor necrosis factor production
GO:0032680 regulation of tumor necrosis factor production
GO:0032760 positive regulation of tumor necrosis factor production
GO:0033173 calcineurin-NFAT signaling cascade
GO:0034644 cellular response to UV
GO:0035239 tube morphogenesis
GO:0035561 regulation of chromatin binding
GO:0035562 negative regulation of chromatin binding
GO:0042692 muscle cell differentiation
GO:0043393 regulation of protein binding
GO:0045333 cellular respiration
GO:0045665 negative regulation of neuron differentiation
GO:0048016 inositol phosphate-mediated signaling
GO:0048167 regulation of synaptic plasticity
GO:0048514 blood vessel morphogenesis
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048754 branching morphogenesis of an epithelial tube
GO:0048813 dendrite morphogenesis
GO:0048814 regulation of dendrite morphogenesis
GO:0050768 negative regulation of neurogenesis
GO:0050773 regulation of dendrite development
GO:0050774 negative regulation of dendrite morphogenesis
GO:0050803 regulation of synapse structure or activity
GO:0050804 modulation of synaptic transmission
GO:0050807 regulation of synapse organization
GO:0050808 synapse organization
GO:0051098 regulation of binding
GO:0051100 negative regulation of binding
GO:0051145 smooth muscle cell differentiation
GO:0051961 negative regulation of nervous system development
GO:0055001 muscle cell development
GO:0060074 synapse maturation
GO:0060562 epithelial tube morphogenesis
GO:0061138 morphogenesis of a branching epithelium
GO:0061614 pri-miRNA transcription from RNA polymerase II promoter
GO:0071214 cellular response to abiotic stimulus
GO:0071241 cellular response to inorganic substance
GO:0071248 cellular response to metal ion
GO:0071285 cellular response to lithium ion
GO:0071478 cellular response to radiation
GO:0071482 cellular response to light stimulus
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0090128 regulation of synapse maturation
GO:0097193 intrinsic apoptotic signaling pathway
GO:0097720 calcineurin-mediated signaling
GO:0198738 cell-cell signaling by wnt
GO:1902893 regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1902894 negative regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production
GO:2000171 negative regulation of dendrite development
GO:2000297 negative regulation of synapse maturation
GO:2001233 regulation of apoptotic signaling pathway
GO:2001235 positive regulation of apoptotic signaling pathway
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001078 transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003713 transcription coactivator activity
GO:0008134 transcription factor binding
GO:0042975 peroxisome proliferator activated receptor binding
Cellular Component GO:0005667 transcription factor complex
GO:0045111 intermediate filament cytoskeleton
> KEGG and Reactome Pathway
 
KEGG hsa04022 cGMP-PKG signaling pathway
hsa04310 Wnt signaling pathway
hsa04360 Axon guidance
hsa04921 Oxytocin signaling pathway
Reactome -
Summary
SymbolNFATC4
Namenuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4
Aliases NFAT3; NF-AT3; NF-ATC4; T-cell transcription factor NFAT3; Nuclear factor of activated T-cells, cytoplasmic ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NFATC4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNFATC4
Namenuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4
Aliases NFAT3; NF-AT3; NF-ATC4; T-cell transcription factor NFAT3; Nuclear factor of activated T-cells, cytoplasmic ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NFATC4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNFATC4
Namenuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4
Aliases NFAT3; NF-AT3; NF-ATC4; T-cell transcription factor NFAT3; Nuclear factor of activated T-cells, cytoplasmic ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NFATC4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9520.0445
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.3050.206
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6970.423
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5840.164
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4730.849
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.7220.824
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0770.881
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.140.91
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0460.972
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.0070.221
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.6590.247
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3980.00282
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NFATC4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNFATC4
Namenuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4
Aliases NFAT3; NF-AT3; NF-ATC4; T-cell transcription factor NFAT3; Nuclear factor of activated T-cells, cytoplasmic ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NFATC4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNFATC4
Namenuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4
Aliases NFAT3; NF-AT3; NF-ATC4; T-cell transcription factor NFAT3; Nuclear factor of activated T-cells, cytoplasmic ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NFATC4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NFATC4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNFATC4
Namenuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4
Aliases NFAT3; NF-AT3; NF-ATC4; T-cell transcription factor NFAT3; Nuclear factor of activated T-cells, cytoplasmic ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NFATC4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNFATC4
Namenuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4
Aliases NFAT3; NF-AT3; NF-ATC4; T-cell transcription factor NFAT3; Nuclear factor of activated T-cells, cytoplasmic ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NFATC4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNFATC4
Namenuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4
Aliases NFAT3; NF-AT3; NF-ATC4; T-cell transcription factor NFAT3; Nuclear factor of activated T-cells, cytoplasmic ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NFATC4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNFATC4
Namenuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4
Aliases NFAT3; NF-AT3; NF-ATC4; T-cell transcription factor NFAT3; Nuclear factor of activated T-cells, cytoplasmic ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NFATC4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.